Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.61 |
| ▸ | CDK1 | P06493 | 9/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836942 | 0.83 | SYK (0.60) | SYK | |
| SCHEMBL4835147 | 0.80 | SYK (0.67) | SYK | |
| SCHEMBL2477250 | 0.78 | SYK (0.66) | SYK | |
| SCHEMBL2471458 | 0.78 | SYK (0.73) | SYK | |
| SCHEMBL2477962 | 0.78 | SYK (0.73) | SYK | |
| SCHEMBL4830934 | 0.77 | LRRK2 (0.43) | SYK | |
| SCHEMBL4839133 | 0.77 | SYK (0.60) | SYK | |
| SCHEMBL4830794 | 0.77 | PRKD1 (0.43) | SYK | |
| SCHEMBL4835097 | 0.75 | SYK (0.41) | SYK | |
| SCHEMBL2221438 | 0.75 | AURKA (0.60) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182849-A1 | Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds | CURRIE KEVIN S | 2008-07-31 | — | — | US | disclosed |
| US-20080182849-A1 | Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds | CURRIE KEVIN S | 2008-07-31 | — | — | US | disclosed |
| US-7393848-B2 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393848-B2 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005005429-A1 | CERTAIN HETEROCYCLIC SUBSTITUTED IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHODS OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | BTK, SYK, LYN | SYK 2/4885CDK1 355/4885ADRA2A 1598/4885 |
| US-20080182849-A1 | Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds | BTK, SYK, LYN | SYK 2/4885CDK1 344/4885ADRA2A 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.